National Bank of Canada
INDV icon

National Bank of Canada’s Indivior Pharmaceuticals INDV Stock Holding History

National Bank of Canada’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22K Sell
722
-14,058
-95% -$464K ﹤0.01% 2155
2025
Q4 		$530K Buy
14,780
+14,136
+2,195% +$432K ﹤0.01% 1341
2025
Q3 		$15.5K Sell
644
-16
-2% -$335 ﹤0.01% 2217
2025
Q2 		$9.89K Hold
660
– – ﹤0.01% 2364
2025
Q1 		$6.21K Sell
660
-60
-8% -$631 ﹤0.01% 2341
2024
Q4 		$9.33K Buy
720
+135
+23% +$1.39K ﹤0.01% 2343
2024
Q3 		$5.7K Hold
585
– – ﹤0.01% 2180
2024
Q2 		$9.16K Hold
585
– – ﹤0.01% 2140
2024
Q1 		$10.6K Hold
585
– – ﹤0.01% 2163
2023
Q4 		$8.97K Sell
585
-180
-24% -$3.2K ﹤0.01% 2192
2023
Q3 		$16.1K Buy
765
+70
+10% +$1.6K ﹤0.01% 2083
2023
Q2 		$16.2K Buy
+695
New +$15.9K ﹤0.01% 2061

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

National Bank of Canada's INDV Position: Q1 2026 in Review

National Bank of Canada reduced its Indivior Pharmaceuticals (INDV) stake by 95% in Q1 2026, selling an estimated $464K and leaving 722 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #2155.

National Bank of Canada first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $530K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • National Bank of Canada held 722 shares of Indivior Pharmaceuticals worth $22K as of Q1 2026.
  • National Bank of Canada sold 14,058 Indivior Pharmaceuticals shares in Q1 2026, an estimated $464K.
  • Indivior Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2155 holding.
  • National Bank of Canada first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • National Bank of Canada's Indivior Pharmaceuticals position peaked at $530K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.